ISSN 2564-7784 | E-ISSN 2564-7040
Case Report
Diabetic Ketoacidosis Occurring in Patient on Newly Started Insulin Glargine U300
1 Department of Internal Medicine, Division of Endocrinology and Metabolism, Selçuk University School of Medicine, Konya, Turkey  
Eur J Ther 2018; 24: 266-267
DOI: 10.5152/EurJTher.2017.293
Key Words: Glargine U300, diabetic ketoacidosis, pharmacokinetic
Abstract

Insulin glargine U300 is a 3-fold, concentrated, long-acting insulin analog providing a more stable effect compared with insulin glargine U100. However, stable plasma insulin concentration is reached on day 4 of the treatment. Patients with type 1 and type 2 diabetes mellitus with decreased insulin reserve are at an increased risk of diabetic ketoacidosis when there is insufficient exogenous plasma insulin concentration. Herein, we present a case of diabetic ketoacidosis occurring in a patient with insulin glargine U300 and emphasize the pharmacokinetic properties of insulin glargine U300.

 

 

How to citeKıraç CO, İpekçi SH, Kebapcılar L. Diabetic Ketoacidosis Occurring in Patient on Newly Started Insulin Glargine U300. Eur J Ther 2018; 24(4): 266-7.

Key Words
Authors
All
Survey
AVES | Copyright © 2019 European Journal of Therapeutics | Latest Update: 28.05.2019